Although β2-GPI was first described in 1961 by Schultze et al. [43], the interest in this protein increased significantly only about thirty years after its discovery, when it was recognized as the major antigenic target in APS [44,45,46]. This evidence concerns the gene APOH and autoimmune polyendocrinopathy.